Celgene psoriasis trial of CC-10004 - apremilast successful

Celgene announced today that its Phase Two trial of CC-10004 (also known as apremilast) showed promise against psoriasis, and the company pledged to accelerate its development for psoriasis and other inflammatory diseases. The treatment is novel in that it is an oral TNF alpha inhibitor; the TNF alpha inhibitors already available are injected or infused, not taken in pill form.

We have more here on the psoriasis research pipeline.